The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No ClinVar Id was directly found from the curated document
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000212.3:c.674del

CA915940689

Gene: ITGB3
Condition: Glanzmann thrombasthenia
Inheritance Mode: Autosomal recessive inheritance
UUID: 56b9e0f9-6006-46e9-ac46-da25eef57b13
Approved on: 2022-05-17
Published on: 2022-06-12

HGVS expressions

NM_000212.3:c.674del
NC_000017.11:g.47286319del
CM000679.2:g.47286319del
NC_000017.10:g.45363685del
CM000679.1:g.45363685del
NC_000017.9:g.42718684del
NG_008332.2:g.37478del
ENST00000559488.7:c.674del
ENST00000559488.5:c.674del
ENST00000560629.1:n.639del
ENST00000571680.1:c.674del
NM_000212.2:c.674del

Pathogenic

Met criteria codes 4
PM2_Supporting PP4_Moderate PM3_Supporting PVS1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Platelet Disorders VCEP
The NM_000212.3:c.674del (p.Gln225ArgfsTer2) variant in ITGB3 exon 5 is a frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 5/15 and is predicted to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). This variant has been detected in at least one proband with Glanzmann thrombasthenia. The reported proband (GT30, PMID: 19691478) was homozygous for the variant (PM3_Supporting). At least one patient (Patient GT30 in PMID: 19691478) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia (PP4_Moderate). Additionally, αIIbβ3 surface expression was reduced to <5%, as measured by flow cytometry. However, ITGA2B and ITGB3 were not reported to be sequenced across all exons and intron/exon boundaries. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PVS1, PM2_Supporting, PM3_Supporting, PP4_Moderate. (VCEP specifications version 2; date of approval 05/17/2022)
Met criteria codes
PM2_Supporting
This variant is absent from gnomAD v2.1.1 (PM2_Supporting).
PP4_Moderate
At least one patient (Patient GT30 in PMID: 19691478) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia (PP4_Moderate). Additionally, αIIbβ3 surface expression was reduced to <5%, as measured by flow cytometry. However, ITGA2B and ITGB3 were not reported to be sequenced across all exons and intron/exon boundaries.
PM3_Supporting
This variant has been detected in at least one proband with Glanzmann thrombasthenia. The reported proband (GT30, PMID: 19691478) was homozygous for the variant (0.5 points). Total points: 0.5 (PM3_Supporting).
PVS1
The c.674del (p.Gln225ArgfsTer2) variant in exon 5 is a frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 5/15 and is predicted to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.